Publications by authors named "J W Kazura"
Background: Identification of local Plasmodium vivax transmission foci and its hidden reservoirs are crucial to eliminating residual vivax malaria transmission. This study assessed whether reactive case detection (RCD) could better identify P. vivax cases and infection incidences in Arjo-Didessa, Southwestern Ethiopia.
View Article and Find Full Text PDFArticle Synopsis
- - Acute lower respiratory tract infection (ALRI) is a leading cause of child mortality globally, particularly affecting children in Papua New Guinea (PNG) due to Streptococcus pneumoniae.
- - Researchers conducted whole-exome sequencing on children in PNG and found a specific genetic variant (a single-nucleotide variant in the COQ6 gene) that is linked to higher morbidity from ALRI, with evidence from both human and mouse studies supporting its role.
- - The COQ6 variant plays a significant role in the biosynthesis of ubiquinone and impacts how the immune system responds to infections, highlighting a new genetic risk factor for pneumonia in PNG and the enzyme's involvement in inflammatory responses.
Article Synopsis
- TEP1 is a protein in mosquitoes that helps resist malaria parasites, prompting this study to explore how TEP1 genetic variations influence malaria infection outcomes in Anopheles arabiensis populations in southwestern Ethiopia.
- Researchers collected mosquito larvae, identified their species, and used PCR techniques to analyze TEP1 genotypes from 330 samples, finding two main alleles, TEP1*S1 and TEP1*R1, in varying frequencies.
- Results showed notable differences in TEP1 allele and genotype frequencies among populations, with the TEP1*RR genotype linked to increased susceptibility to Plasmodium oocyst development in mosquitoes.
Narrowing the Gap in Managing the Lymphedema of Lymphatic Filariasis.
Am J Trop Med Hyg
October 2024
Background: To interrupt residual malaria transmission and achieve successful elimination of Plasmodium falciparum in low-transmission settings, the World Health Organization (WHO) recommends the administration of a single dose of 0.25 mg/kg (or 15 mg/kg for adults) primaquine (PQ) combined with artemisinin-based combination therapy (ACT), without glucose-6-phosphate dehydrogenase (G6PD) testing. However, due to the risk of haemolysis in patients with G6PD deficiency (G6PDd), PQ use is uncommon.
View Article and Find Full Text PDF